Method of treatment using a pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and its cofactor
AssigneeErytech Pharma
InventorsYann Godfrin, Vanessa Bourgeaux, Fabien Gay, Thomas Cortese
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.
Claims15
A therapeutic treatment method for depleting or reducing a plasma or circulating substrate selected from the group consisting of methionine, homocysteine and tyrosine in a patient in need thereof comprising administering an effective amount of a composition comprising erythrocytes encapsulating a pyridoxal phosphate (PLP)-dependent enzyme and administering an effective amount of a non-phosphate form of vitamin B6, wherein the composition and the non-phosphate form of vitamin B6 are administered separately or sequentially;
- wherein the administration of the effective amount of the non-phosphate form of vitamin B6 and the effective amount of the encapsulated PLP-dependent enzyme produces greater residual PLP-dependent enzyme activity than administration of the same amount of the vitamin B6 and the same amount of a non-encapsulated, free form of the PLP-dependent enzyme.
A therapeutic treatment method for depleting or reducing a plasma or circulating substrate selected from the group consisting of methionine, homocysteine and tyrosine in a patient in need thereof, comprising:
- a) administering an effective amount of a composition comprising erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating a PLP-dependent enzyme and pyridoxal phosphate (PLP), and
- b) administering a non-phosphate form of vitamin B6 in an amount effective to maintain the encapsulated PLP-dependent enzyme in its holoenzyme form longer relative to the same PLP-dependent enzyme not encapsulated in erythrocytes;
- wherein the composition and the non-phosphate form of vitamin B6 are administered separately or sequentially.
Dependencies are inferred from the claim text.